Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Ovarian cancer mutational processes drive site-specific immune evasion

ABSTRACT: Ovarian cancer mutational processes drive site-specific immune evasion

PROVIDER: PRJNA749041 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR15217200_1.fastq.gz	Fastqsanger.gz
	SRR15217200_2.fastq.gz	Fastqsanger.gz
	SRR15217300_1.fastq.gz	Fastqsanger.gz
	SRR15217300_2.fastq.gz	Fastqsanger.gz
	SRR15217400_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 1118

Similar Datasets

Ovarian cancer mutational processes drive site-specific immune evasion

Project description:High-grade serous ovarian cancer (HGSOC) is an archetypal cancer of genomic instability patterned by distinct mutational processes, tumour heterogeneity and intraperitoneal spread. Immunotherapies have had limited efficacy in HGSOC, highlighting an unmet need to assess how mutational processes and the anatomical sites of tumour foci determine the immunological states of the tumour microenvironment. Here we carried out an integrative analysis of whole-genome sequencing, single-cell RNA sequencing, digital histopathology and multiplexed immunofluorescence of 160 tumour sites from 42 treatment-naive patients with HGSOC. Homologous recombination-deficient HRD-Dup (BRCA1 mutant-like) and HRD-Del (BRCA2 mutant-like) tumours harboured inflammatory signalling and ongoing immunoediting, reflected in loss of HLA diversity and tumour infiltration with highly differentiated dysfunctional CD8+ T cells. By contrast, foldback inversion-bearing tumours exhibited elevated immunosuppressive TGFβ signalling and immune exclusion, with predominantly naive/stem-like and memory T cells. Phenotypic state associations were specific to anatomical sites, highlighting compositional, topological and functional differences between adnexal tumours and distal peritoneal foci. Our findings implicate anatomical sites and mutational processes as determinants of evolutionary phenotypic divergence and immune resistance mechanisms in HGSOC. Our study provides a multi-omic cellular phenotype data substrate from which to develop and interpret future personalized immunotherapeutic approaches and early detection research.

2022-12-14 | GSE180661 | GEO

Ovarian cancer mutational processes drive site-specific immune evasion.

Project description:High-grade serous ovarian cancer (HGSOC) is an archetypal cancer of genomic instability1-4 patterned by distinct mutational processes5,6, tumour heterogeneity7-9 and intraperitoneal spread7,8,10. Immunotherapies have had limited efficacy in HGSOC11-13, highlighting an unmet need to assess how mutational processes and the anatomical sites of tumour foci determine the immunological states of the tumour microenvironment. Here we carried out an integrative analysis of whole-genome sequencing, single-cell RNA sequencing, digital histopathology and multiplexed immunofluorescence of 160 tumour sites from 42 treatment-naive patients with HGSOC. Homologous recombination-deficient HRD-Dup (BRCA1 mutant-like) and HRD-Del (BRCA2 mutant-like) tumours harboured inflammatory signalling and ongoing immunoediting, reflected in loss of HLA diversity and tumour infiltration with highly differentiated dysfunctional CD8+ T cells. By contrast, foldback-inversion-bearing tumours exhibited elevated immunosuppressive TGFβ signalling and immune exclusion, with predominantly naive/stem-like and memory T cells. Phenotypic state associations were specific to anatomical sites, highlighting compositional, topological and functional differences between adnexal tumours and distal peritoneal foci. Our findings implicate anatomical sites and mutational processes as determinants of evolutionary phenotypic divergence and immune resistance mechanisms in HGSOC. Our study provides a multi-omic cellular phenotype data substrate from which to develop and interpret future personalized immunotherapeutic approaches and early detection research.

| S-EPMC9771812 | biostudies-literature

CEBPB-high dormant tumor cells drive immune evasion [ChIP-Seq]

Project description:CEBPB-high dormant tumor cells drive immune evasion [ChIP-Seq]

| PRJNA1225950 | ENA

CEBPB-high dormant tumor cells drive immune evasion [RNA-Seq]

Project description:CEBPB-high dormant tumor cells drive immune evasion [RNA-Seq]

| PRJNA1225951 | ENA

Cancer suppresses mitochondrial chaperone activity in macrophages to drive immune evasion

Project description:Cancer suppresses mitochondrial chaperone activity in macrophages to drive immune evasion

| PRJNA1174208 | ENA

Single cell genome variation induced by mutational processes in cancer - HGSOC Trios study

Project description:Single cell genome variation induced by mutational processes in cancer - HGSOC Trios study

| PRJNA871025 | ENA

Single cell genome variation induced by mutational processes in cancer - HGSOC Trios study

Project description:Single cell genome variation induced by mutational processes in cancer - HGSOC Trios study

| PRJNA871024 | ENA

Copy number signatures and mutational processes in ovarian carcinoma.

Project description:The genomic complexity of profound copy number aberrations has prevented effective molecular stratification of ovarian cancers. Here, to decode this complexity, we derived copy number signatures from shallow whole-genome sequencing of 117 high-grade serous ovarian cancer (HGSOC) cases, which were validated on 527 independent cases. We show that HGSOC comprises a continuum of genomes shaped by multiple mutational processes that result in known patterns of genomic aberration. Copy number signature exposures at diagnosis predict both overall survival and the probability of platinum-resistant relapse. Measurement of signature exposures provides a rational framework to choose combination treatments that target multiple mutational processes.

| S-EPMC6130818 | biostudies-literature

Mutational signatures

Project description:Mutational signatures

| PRJEB60585 | ENA

mTORC1 upregulates B7-H3/CD276 to inhibit antitumor T cells and drive tumor immune evasion

Project description:mTORC1 upregulates B7-H3/CD276 to inhibit antitumor T cells and drive tumor immune evasion

| PRJNA883227 | ENA